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The successful development of targeted nanotherapeutics is contingent upon the conjugation of
therapeutic nanoparticles to target-speciﬁc ligands, with particular emphasis being placed on antibody-
based ligands. Thus, new methods that enable the covalent and precise installation of targeting
antibodies to nanoparticle surfaces are greatly desired, especially those which do not rely on costly and
time-consuming antibody engineering techniques. Herein we present a novel method for the highly
controlled and oriented covalent conjugation of non-engineered antibody F(ab) fragments to PLGA–PEG
nanoparticles using disulﬁde-selective pyridazinedione linkers and strain-promoted alkyne–azide click
chemistry. Exempliﬁcation of this method with trastuzumab and cetuximab showed signiﬁcant
improvements in both conjugation eﬃciency and antigen binding capability, when compared to
commonly employed strategies for antibody–nanoparticle construction. This new approach paves the
way for the development of antibody-targeted nanomedicines with improved paratope availability,
reproducibility and uniformity to enhance both biological activity and ease of manufacture.Introduction
The application of nanoparticles as drug delivery vehicles has
attracted signicant interest owing to potential benets of these
platforms, such as improved pharmacokinetic and safety
proles of encapsulated cargo. Several nanoformulations are
now marketed, whilst numerous others are under clinical
evaluation.1,2 Many nanoformulations are developed for
oncology applications in particular.3 Nanoparticles can
‘passively’ accumulate within tumours by exploiting defects in
neovasculature endothelial junctions and impaired lymphatic
drainage, a phenomenon known as the enhanced permeability
and retention (EPR) eﬀect. However, surface functionalisation
of nanoparticles with targeting ligands has the potential tology, School of Medicine, Dentistry and
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hemistry 2018signicantly enhance cellular uptake and retention at the
tumour site in a concept referred to as ‘active’ targeting.4–6
A variety of ligands have been explored for such purposes,
including aptamers, peptides and carbohydrates, although
antibodies are perhaps the most frequently employed.7–10
Numerous bioconjugation methods exist to gra these ligands
to the surface of nanoparticles, with common approaches
including carbodiimide and maleimide chemistries.11,12 Car-
bodiimide coupling involves the derivatisation of a carboxyl
group with cross-linking agents such as 1-ethyl-3-(-3-
dimethylaminopropyl) carbodiimide (EDC), followed by their
direct conjugation to amines resulting in the generation of an
amide bond. Depending on the direction of the conjugation,
antibodies can be coupled to nanoparticles by virtue of free
amine or carboxyl functionalities on lysine or aspartic/glutamic
acid residues, respectively. However, this approach is encum-
bered by low reaction eﬃciencies and generates highly hetero-
geneous nanoconjugates, where optimal orientation and
functionality of paratopes cannot be guaranteed due to the high
abundance of reactive amine- and carboxyl-containing residues
throughout antibodies. Alternatively, maleimide chemistry can
in theory facilitate site-specic conjugation to cysteine residues
liberated by the reduction of the inter-strand disulde bonds of
antibodies.12–14 However, multiple reports have questioned the
cysteine selectivity of maleimide conjugation under commonly
employed conditions,15,16 and the resultant bioconjugate would
bear a thioether bond that has been shown to be inherentlyChem. Sci., 2018, 9, 79–87 | 79
Fig. 1 Comparison of site-speciﬁc conjugation approach versus conventional NHS coupling. Use of a novel heterobifunctional linker permits the
controlled assembly of a surface corona of F(ab) targeting ligands on nanoparticles. The concentrated display of oriented and accessible par-
atopes aﬀorded by this approach maximises target interactions, leading to signiﬁcantly enhanced avidity versus conventional coupling
chemistries.





















































































View Article Onlineunstable in vivo.17–19 Furthermore this strategy results in the loss
of a covalent link between antibody chains. Nonetheless,
reports throughout the literature demonstrate the advantages of
utilising other site-specic chemistries for the generation of
nanoconjugates, including improved antigen binding and
greater product homogeneity.9,12,20,21 Many of these approaches
involve the installation of site-selective amino acid residues
using site-directed mutagenesis, followed by subsequent pair-
ing with an appropriate reactive group on the nanoparticle
surface.9,14,22–26 Whilst this approach allows for the oriented
presentation of antibody ligands, it is restricted by the need for
time consuming and expensive antibody engineering.
Given these challenges, novel strategies are required to rene
antibody conjugation to nanoparticles, with emphasis on: (i)
optimising the presentation of the antibody for maximal inter-
action with cognate targets; and (ii) improving the homogeneity
and eﬃciency of conjugation of antibodies in their native state to
aid manufacturability. Previously, we described a novel approach
for the functional re-bridging of native inter-strand disulde
bonds of full antibodies and their constituent fragments, i.e.
resulting in no loss of covalent linkage between antibody chains
and modifying at positions that are distal from the antibody
binding site.27–33 This involved the selective insertion of pyr-
idazinedione moieties bearing reactive handles into reduced
disulde bonds, thus enabling site-specic incorporation of ‘click’
domains without impinging upon antibody functionality. Here we
describe the application of this disulde re-bridging technology to
site-selectivelymodify trastuzumab (TRAZ) F(ab) to bear a strained
alkyne handle distal to the paratope and conjugate it to azide-
functionalised nanoparticles. This novel approach is compared80 | Chem. Sci., 2018, 9, 79–87to conventional methods in order to determine the importance of
chemical strategy on the performance of nanoconjugates (Fig. 1).
We demonstrate superior binding to HER2 of nanoconjugates
formed by our new method versus NHS ester conjugation, high-
lighting the potential of this approach to overcome the short-
comings of conventional coupling chemistries employed in many
targeted nanoformulations to date.Results and discussion
Our study began with the synthesis of a novel heterobifunc-
tional linker that would facilitate conjugation to an antibody
disulde at one end and attachment to a nanoparticle at the
other. For attachment to the nanoparticle surface, we decided to
incorporate the strained alkyne BCN due to its ability to engage
in copper free strained-promoted alkyl-azide cycloaddition
(SPAAC) reactions and our condence in being able to formu-
late azide-functionalised nanoparticles (discussed in detail
below). Despite wide-spread use within biomedical research,
SPAAC has remained largely unexplored for the generation of
nanoconjugates and we took this opportunity to appraise it in
this light. To impart site-selective protein reactivity to the linker,
the BCN moiety was linked to a dibromopyridazinedione,
chosen for its exquisite disulde reactive selectivity and the
excellent stability prole of antibody conjugates formed thereof.
Synthesis of the strained alkyne functionalised pyridazinedione
3 proceeded from readily available starting materials in a facile
manner over three steps (Scheme 1, further details on the
synthetic methods can be found in S1–S5 in the ESI†).This journal is © The Royal Society of Chemistry 2018





















































































View Article OnlineThe monoclonal antibody TRAZ was chosen as a targeting
ligand due to its clinical relevance as an approved therapeutic
against HER2+ breast cancers.34 The choice to utilise the F(ab)
domain of TRAZ as the targeting component was driven
primarily by the growing volume of evidence suggesting anti-
body fragments provide multiple benets to the overall perfor-
mance of nanoconjugates when compared to full antibodies;
F(ab)s retain the binding component of a full antibody.9 Addi-
tionally, the use of the F(ab) domain is ideal in that it only
contains a single solvent accessible disulde bond to ensure
homogeneous modication and that there is only a single site
from which the antibody ligand can be attached to the nano-
particle. Furthermore, F(ab) domains can be readily expressed
and/or obtained from native full antibody scaﬀolds via simple
enzymatic digestion procedures. In this particular case, we ob-
tained TRAZ F(ab) from native TRAZ via enzymatic digestion
(pepsin followed by papain, further details provided in the
ESI†). Site-selective modication of TRAZ F(ab) with strained
alkyne-pyridazinedione 3 was achieved according to previously
reported protocols31 (Fig. 2A) and conrmed using LCMS
(Fig. 2B and S9†), and SDS-PAGE showed no aggregation or
fragmentation (Fig. S8†) (hereaer referred to as modied TRAZ
F(ab) [disulde] 5). A test click reaction with Alexauor-488®-
azide conrmed the presence of the strained alkyne (Fig. S10
and S11†). As an appropriate control to determine the overall
eﬀect of the site-directed chemistry, a strained alkyne was
incorporated into TRAZ F(ab) using non-site-selective lysine-
NHS chemistry (modied TRAZ F(ab) [lys]) (Fig. S13 and
S14†). Additionally, the F(ab) fragment of cetuximab (CTX) was
site-selectively modied to provide a control for antigen target
specicity (modied CTX F(ab) [disulde]) (Fig. S17 and S18†).
CTX was considered a suitable targeting ligand control in this
context, given that it does not engage HER2 but rather binds to
EGFR, another member of the ErbB family of receptor tyrosine
kinases.35
Following preparation of the various F(ab) domains, we next
explored the potential for site-specic functionalisation of
nanoparticles with modied TRAZ F(ab) [disulde] 5. ToScheme 1 Synthesis of strained alkyne functionalised pyridazinedione
3. Reagents and conditions: (i) dibromomaleic acid, AcOH, reﬂux, 24 h;
(ii) PyBOP, DIPEA, CH2Cl2, 21 C, 16 h.
This journal is © The Royal Society of Chemistry 2018facilitate ‘click’ conjugation to this antibody fragment, a novel
PLGA nanoparticle incorporating a complementary azide
moiety was developed. A single emulsion solvent evaporation
approach was employed to generate a homogeneous population
of azide-terminated nanoparticles from a 25% : 75% polymer
blend of PLGA–PEG-azide and PLGA RG502H (nude azide NP)
(Table 1). These nanoparticles were subjected to stability
assessment over several months, with no signicant change in
physicochemical characteristics observed upon storage at 4 C
or 20 C (Fig. S19†). Conjugation of modied TRAZ F(ab)
[disulde] 5 to azide-functionalised nanoparticles was then
enabled by incubating both components for 2 h under ambient
conditions, yielding a nanoconjugate with a protein loading of
193.1  49.9 pmoles per mg polymer (modied TRAZ F(ab) NP
[disulde]) (Table 1). Contrary to our approach, similar reports
of the ‘click’ functionalisation of nanoparticles via alkyne–azide
cycloaddition most oen involve copper catalysis, which can
impart toxicities that ultimately limit the biomedical applica-
tion of the nanoconjugate.36–40 A range of equimolar controls
were also formulated in parallel, which included: (i) native
TRAZ F(ab) 4 conjugated to NHS-functionalised nanoparticles
(native TRAZ F(ab) NP), (ii) modied TRAZ F(ab) [lys] conjugated
to azide-functionalised nanoparticles, with the linker chemistry
being introduced at lysine residues as opposed to reduced
disuldes (modied TRAZ F(ab) NP [lys]), (iii) native CTX F(ab)Fig. 2 Modiﬁcation of TRAZ F(ab) with strained alkyne functionalised
pyridazinedione 3. (A) Scheme 2: reagents and conditions: (i) 3,
TCEP$HCl, BBS pH ¼ 8.0 (2 mM EDTA), 4 C, 15 h; (ii) Alexaﬂuor®-
488-N3 BBS pH ¼ 8.0 (2 mM EDTA). (B) LCMS data showing native 4,
conjugated 5, and clicked TRAZ F(ab) 6. Spectra have been annotated
for clarity, see Fig. S7, S9 and S12 in the ESI† for full spectral data.
Chem. Sci., 2018, 9, 79–87 | 81
Fig. 3 ESEM imaging of nanoformulations. (A) Modiﬁed TRAZ F(ab) NP
[disulﬁde] and (B) native TRAZ F(ab) NP were dried on double-sided
copper tapemounted onto aluminium stubs, sputter-coated with gold
and imaged with an ESEM. Scale bar ¼ 4 mm.





















































































View Article Onlineconjugated to NHS-functionalised nanoparticles (native CTX
F(ab) NP) and (iv) modied CTX F(ab) [disulde] conjugated
to azide-functionalised nanoparticles (modied CTX F(ab)
NP [disulde]) (Table 1). Quantication of F(ab) content
within these nanoformulations revealed that conjugation via
the strained alkyne proceeded with much greater eﬃciency
compared to NHS ester chemistry (Table 1). These ndings
are consistent with the enhanced reaction kinetics of SPAAC
click chemistry over NHS ester chemistry and also the
improved stability of the surface bound azide when
compared to the activated carboxylic acid. Further charac-
terisation experiments included ESEM imaging, which
revealed the spherical morphology and uniform size distri-
bution of selected nanoformulations, with similar diameters
to those acquired via dynamic light scattering (DLS) in
Table 1 (Fig. 3).
Having successfully developed modied TRAZ F(ab) NP
[disulde], we next explored the ability of the nanoconjugate
to bind to the HER2 target receptor. Initial studies employed
surface plasmon resonance (SPR) to examine binding activity
towards a HER2 fusion protein immobilised on a carboxy-
methylated dextran chip. Although binding of native TRAZ
F(ab) NP was detected via SPR, an equivalent polymer
concentration of modied TRAZ F(ab) NP [disulde] showed
a signicantly enhanced binding prole (Fig. 4A). No appre-
ciable binding of nude NP (both NHS and azide) or CTX F(ab)
NP (both native and modied) controls was observed, con-
rming the dependence of the interaction on TRAZ F(ab).
Moreover, HER2 binding of modied TRAZ F(ab) NP [lys] was
also negligible despite highly eﬃcient coupling of the frag-
ment to nanoparticles (see Table 1), indicating that this
conjugation approach restricted paratope accessibility. This
comparison demonstrates that the site-selective nature of
pyridazinedione conjugation to F(ab) plays a critical role in
the observed improvements in antigen binding; indicating
improved paratope accessibility granted by the oriented
display of the fragments on the nanoparticle surface.
To exclude the possibility that enhanced binding of modied
TRAZ F(ab) NP [disulde] is a consequence of free F(ab)
complexation rather than direct coupling to nanoparticles, we




Nude NHS NP PLGA–PEG-NHS 191.1  1.2 0.16  0.0
Native TRAZ F(ab) NP PLGA–PEG-NHS 210.4  2.7 0.18  0.0
Native CTX F(ab) NP PLGA–PEG-NHS 191.2  1.8 0.11  0.0
Nude azide NP PLGA–PEG-azide 187.4  1.8 0.02  0.0
Modied TRAZ F(ab)
NP [disulde]
PLGA–PEG-azide 192.4  1.5 0.05  0.0
Modied TRAZ F(ab)
NP [lys]
PLGA–PEG-azide 207.4  0.1 0.13  0.0
Modied CTX F(ab)
NP [disulde]
PLGA–PEG-azide 189.9  0.2 0.05  0.0
a Data expressed as mean  SD. b Equimolar amounts of each F(ab) dom
82 | Chem. Sci., 2018, 9, 79–87Rhodamine 6G was encapsulated within the various nano-
formulations to enable a uorescent readout of binding to
immobilised HER2 fusion protein. These studies producedZeta potentiala
(mV)
F(ab) conjugated
(pmoles per mg polymer)a,b
Conjugation
eﬃciencya (%)
1 4.6  0.6 — —
1 3.5  0.1 65.3  24.0 6.2  2.3
1 3.9  0.4 103.8  29.1 9.9  2.8
1 2.7  0.6 — —
2 1.9  0.7 193.1  49.9 18.4  4.7
2 3.1  0.3 475.0  221.7 45.2  21.1
1 2.3  0.1 208.4  86.5 19.8  8.2
ain were initially added to the nanoparticle conjugation reaction.
This journal is © The Royal Society of Chemistry 2018
Fig. 4 Enhanced binding of modiﬁed TRAZ F(ab) NP [disulﬁde] to
HER2 versus native TRAZ F(ab) NP. (A) HER2 binding activity of native
TRAZ F(ab) NP, modiﬁed TRAZ F(ab) NP [disulﬁde] and associated
controls (10 mg polymer per mL) was assessed by SPR. (B) HER2
binding activity of rhodamine 6G-loaded native TRAZ F(ab) NP,
modiﬁed TRAZ F(ab) NP [disulﬁde] and associated controls (200 mg
polymer per mL) was assessed by modiﬁed ELISA. Data expressed as
mean  SEM. Statistical signiﬁcance was established by one-way
ANOVA and Tukey's post-hoc test (****p # 0.0001).
Fig. 5 HER2 targeting speciﬁcity of TRAZ F(ab) NP. (A) HER2 binding
activity of (i) native TRAZ F(ab) NP, (ii) modiﬁed TRAZ F(ab) NP [disul-
ﬁde] and associated controls (200 mg polymer per mL) was assessed by
modiﬁed ELISA  pre-block with TRAZ full antibody (20 mg mL1). (B)
HER2 binding activity of modiﬁed TRAZ F(ab) NP [disulﬁde] (200 mg
polymer per mL) was assessed by modiﬁed ELISA in competition with
TRAZ full antibody (0.000051–20 mgmL1). Data expressed as mean
SEM. Statistical signiﬁcance was established by one-way ANOVA and
Tukey's post-hoc test (****p # 0.0001).





















































































View Article Onlinesimilar trends to earlier SPR analyses, demonstrating superior
binding to HER2 of modied TRAZ F(ab) NP [disulde] versus
native TRAZ F(ab) NP and associated controls (Fig. 4B).
Consistent with our ndings, direct comparisons of carbodii-
mide and click chemistry-based approaches for nanoparticle
functionalisation have also been described in the literature with
a similar enhancement in targeting eﬃciency conferred by the
latter.41–45 Several of these reports employ full antibodies as
targeting ligands whereas our approach oﬀers a distinct
advantage through the use of F(ab) fragments comprising a sole
disulde bond. This ensures that the click-reactive handle is
exclusively installed at a single site located distal from the
paratope.
The HER2 targeting specicity of modied TRAZ F(ab) NP
[disulde] and native TRAZ F(ab) NP was next validated via
modied ELISA, where pre-incubation of HER2-coated wellsThis journal is © The Royal Society of Chemistry 2018 Chem. Sci., 2018, 9, 79–87 | 83
Fig. 6 Enhanced binding of modiﬁed TRAZ F(ab) NP [disulﬁde] is not attributed to improved protein conjugation. (A) HER2 binding activity of
native TRAZ F(ab) NP or modiﬁed TRAZ F(ab) NP [disulﬁde] (10 mg polymer per mL) with various protein loadings was assessed by SPR.
Representative sensorgram shown, with corresponding details for numbered samples in the below table. (B) HER2 binding activity of native TRAZ
F(ab) NP or modiﬁed TRAZ F(ab) NP [disulﬁde] (400 mg polymer per mL) with various protein loadings was assessed by modiﬁed ELISA. Protein
loadings are expressed as pmoles of F(ab) per mg polymer. Data expressed as mean  SEM.





















































































View Article Onlinewith an excess of TRAZ full antibody signicantly impeded
nanoparticle binding (Fig. 5Ai and 5Aii). These ndings were
further bolstered by competition modied ELISA formats,
where simultaneous addition of TRAZ full antibody and modi-
ed TRAZ F(ab) NP [disulde] to HER2-coated wells inhibited
nanoparticle binding in a concentration-dependent manner
(Fig. 5B). Collectively, these results demonstrate the successful84 | Chem. Sci., 2018, 9, 79–87coupling of TRAZ F(ab) domains to NHS- and azide-
functionalised nanoparticles by distinct approaches, gener-
ating active nanoconjugates with retained binding capacity for
the cognate HER2 antigen.
We next examined the basis for the enhanced HER2 binding
activity of the nanoconjugate generated using the site-selective
chemistry, modied TRAZ F(ab) NP [disulde]. To assessThis journal is © The Royal Society of Chemistry 2018
Fig. 7 Validation of TRAZ F(ab) functionality in cell-based assays. (A)
Confocal microscopy images of HCC1954 cells treated with modiﬁed
TRAZ F(ab) NP [disulﬁde] encapsulating nile red (400 mg polymer
per mL)  TRAZ full antibody (200 mg mL1) for 18 h. Blue and red
staining denote nuclei and nanoparticles, respectively. Scale bar ¼
25 mm. (B) BT474 cells were treated with (i) native TRAZ F(ab) NP or (ii)
modiﬁed TRAZ F(ab) NP [disulﬁde] and associated controls (500 mg
polymer per mL). CellTiter-Glo assay was performed at 48, 96 and
144 h following treatment. Data expressed as mean  SEM.





















































































View Article Onlinewhether this eﬀect was simply attributed to enhanced F(ab)
loading on the nanoconjugate rather than optimised paratope
orientation, we formulated both native TRAZ F(ab) NP and
modied TRAZ F(ab) NP [disulde] using various input
amounts of the antibody fragments, ranging from approxi-
mately 210 to 2100 pmoles per mg polymer. Higher loadings of
modied TRAZ F(ab) [disulde] 5 on azide-functionalised
nanoparticles were observed, with stepwise increases in
coupling that correlated with the initial amount of F(ab) added,
highlighting the unique degree of control aﬀorded by this
conjugation approach (Fig. 6A). As before, enhanced binding of
modied TRAZ F(ab) NP [disulde] was observed upon SPR
analysis, even when the F(ab) loading was almost half that of
native TRAZ F(ab) NP (Fig. 6A, nanoformulations 5 and 8). This
suggests that signicant benets can be achieved even in the
case of lower F(ab) loadings, establishing the positive eﬀect of
using more controlled (enabling orientation) chemistries.
Intriguingly, this data also revealed that HER2 binding activity
diminished with higher loadings of modied TRAZ F(ab)
[disulde] 5 on nanoparticles, suggestive of potential steric
hindrance eﬀects leading to suboptimal paratope display. Using
uorescently labelled nanoparticles, these studies were repli-
cated via modied ELISA, with comparable ndings to SPR
analyses (Fig. 6B).
Binding of modied TRAZ F(ab) NP [disulde] to HER2 was
then evaluated in amore biologically relevant context using cell-
based assays. The nanoconjugate was uorescently labelled via
encapsulation of nile red and incubated with the HER2-positive
HCC1954 breast cancer line (Fig. S20†), with confocal micros-
copy demonstrating a clear association of modied TRAZ F(ab)
NP [disulde] with these cells (Fig. 7A). Co-incubation with an
excess of TRAZ full antibody markedly ablated uorescent
labeling of the cells, indicating that the binding of the modied
TRAZ F(ab) NP [disulde] was HER2-dependent.
In a nal series of studies, we examined the therapeutic
eﬀects of the TRAZ F(ab) nanoconjugates in vitro. These exper-
iments could not be undertaken with the HCC1954 cell line
used for confocal analyses, given that it shows limited sensi-
tivity to TRAZ. However, numerous reports have demonstrated
that TRAZ full antibody or its constituent fragments can reduce
the viability of BT474 breast cancer cells and so this line was
deemed an appropriate model following conrmation of HER2
expression (Fig. S20†).46–49 Here, we assessed whether TRAZ
F(ab) could induce a similar reduction in viability of BT474 cells
when presented in a nanoparticle-bound format. Whilst treat-
ment with free native TRAZ F(ab) 4 led to a gradual reduction in
cell viability over time as anticipated, this eﬀect was much less
pronounced for the corresponding nanoconjugate (Fig. 7Bi).
However, upon treatment with modied TRAZ F(ab) NP [disul-
de], the reduction in cell viability was much more comparable
to free modied TRAZ F(ab) [disulde] 5 (Fig. 7Bii). These
ndings are consistent with enhanced paratope accessibility on
modied TRAZ F(ab) NP [disulde] conferred via the site-
specic conjugation approach. Importantly, these studies also
conrmed that the installation of a pyridazinedione linker did
not adversely aﬀect the functionality of TRAZ F(ab). Previous
work by ourselves and others has shown that antibody displayThis journal is © The Royal Society of Chemistry 2018on nanoparticle surfaces can enhance receptor cross-linking;
thus mimicking ligand interactions to enhance downstream
biological eﬀects.8,50,51 However, as HER2 is a ligand-less
receptor, it is not surprising that no enhancement of the
eﬀect on cell viability was observed with these particular non-
drug loaded nanoconjugates.
To conclude, we have described a novel strategy for the site-
specic functionalisation of nanoparticles that promotes the
uniform and outward projection of paratopes for maximal
target interaction. Using TRAZ F(ab) as a model platform, we
demonstrate the successful re-bridging of the inter-chain
disulde bond with a heterobifunctional linker andChem. Sci., 2018, 9, 79–87 | 85





















































































View Article Onlinesubsequent ‘click’ coupling to nanoparticles bearing comple-
mentary azide moieties. The controlled orientation of TRAZ
F(ab) aﬀorded by this approach leads to superior binding to
HER2 when compared with conventional NHS ester coupling
chemistry, with retention of F(ab) functionality in cell-based
assays, demonstrating the importance of controlled chemical
ligation for nanoconjugate performance. Crucially, these nd-
ings also extend to other receptor-ligand pairings including
EGFR-cetuximab (Fig. S21†), highlighting the versatility of this
novel approach and how it may be tailored for diverse applica-
tions. This work oﬀers a signicant contribution to the ongoing
endeavor to rene nanoconjugate design, with the aim of
generating more controlled, homogeneous systems that can be
readily translated.Conﬂicts of interest
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